Each vial contains 10 mg of research‑grade Retatrutide.

Retatrutide is a triple‑agonist peptide that interacts with GLP‑1, GIP, and GCGR receptors, offering a versatile tool for investigators studying metabolic signaling pathways. This compound is supplied for laboratory research purposes only and is not approved for diagnostic, therapeutic, or consumptive use.